Robbins Farley’s AstraZeneca AZN Stock Holding History

Robbins Farley’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.38M	Buy	27,096 +1,461	+6%	+$243K	1.67%	30
2026 Q2	$4.86M	Buy	25,635 +498	+2%	+$93.7K	1.87%	25
2026 Q1	$4.96M	Buy	25,137 +184	+0.7%	+$35.5K	2.19%	19
2025 Q4	$4.59M	Sell	24,953 -2,122	-8%	-$372K	2.08%	22
2025 Q3	$4.15M	Buy	27,075 +13,791	+104%	+$2.09M	1.73%	29
2025 Q2	$1.86M	Buy	+13,284	New	+$1.86M	0.86%	45
2023 Q4	–	Sell	-200	Closed	-$27.1K	–	178
2023 Q3	$27.1K	Hold	200	–	–	0.02%	95
2023 Q2	$28.6K	Hold	200	–	–	0.02%	85
2023 Q1	$27.8K	Hold	200	–	–	0.02%	89
2022 Q4	$27.1K	Hold	200	–	–	0.02%	84
2022 Q3	$22K	Hold	200	–	–	0.02%	78
2022 Q2	$26K	Buy	+200	New	+$26.2K	0.03%	58
2022 Q1	–	Sell	-200	Closed	-$23K	–	132
2021 Q4	$23K	Hold	200	–	–	0.02%	69
2021 Q3	$24K	Hold	200	–	–	0.02%	77
2021 Q2	$24K	Hold	200	–	–	0.03%	47
2021 Q1	$22K	Buy	+200	New	+$20.1K	0.02%	78

Other funds holding AZN

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Border to Coast Pensions Partnership Leeds, United Kingdom $7.27B AUM 24.98% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $10.1B AUM 30.4% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

ZWJ Investment Counsel Atlanta, Georgia $3.24B AUM 31.6% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.31B AUM 25.55% 1-Year Est. Return

Oslo Pensjonsforsikring Oslo $863M AUM 18.29% 1-Year Est. Return

Robbins Farley's AZN Position: Q3 2026 in Review

Robbins Farley increased its AstraZeneca (AZN) stake by 5.7% in Q3 2026, buying an estimated $243K and bringing the position to 27,096 shares worth $4.38M. The position accounts for 1.67% of the portfolio, ranked #30.

Robbins Farley first reported a position in AZN in Q1 2021 and has held it in 16 quarters since. The position peaked at $4.96M in Q1 2026. 306 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Robbins Farley held 27,096 shares of AstraZeneca worth $4.38M as of Q3 2026.
Robbins Farley bought 1,461 AstraZeneca shares in Q3 2026, an estimated $243K.
AstraZeneca made up 1.67% of Robbins Farley's portfolio in Q3 2026, its #30 holding.
Robbins Farley first reported a position in AstraZeneca in Q1 2021 and has held it in 16 quarters since.
Robbins Farley's AstraZeneca position peaked at $4.96M in Q1 2026.
306 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Robbins Farley's 13F filing for Q3 2026, filed 21 Oct 2026.